Search adipotide before and after and you get human bodies. The published before and after is 10 obese rhesus monkeys at MD Anderson, weighed over 28 days in 2011.
The short answer. The measured adipotide before and after is 10 rhesus monkeys over 28 days in 2011, averaging about 11% weight loss.
- The human trial NCT01262664 enrolled four people, was terminated, and posted no results.
- The mechanism is cytotoxic: it kills blood vessels feeding white fat. It is not an appetite or metabolic drug.
- The animal data identified the kidney as the dose-limiting organ, with creatinine rising above 0.25 mg/kg.
Adipotide has no published human weight-loss result. The real data is a 2011 monkey study. Those animals lost about 11% of body weight in 28 days. Kidney markers rose at the higher doses. The human trial, NCT01262664, enrolled four people. It was terminated and posted no results.
What was actually measured
The source of every adipotide number is one paper: Barnhart and colleagues, Science Translational Medicine, 2011. The subjects were spontaneously obese rhesus monkeys.
Treated animals received 0.43 mg/kg under the skin, once a day, for 28 days. Ten treated monkeys lost between 7.4% and 14.7% of body weight. The group mean sat near 11%.
The paper also reported improved insulin resistance in the same animals, and a drop in abdominal fat on imaging. That is a real result. It is also a result in four-legged primates on a controlled diet in a research facility.
- Species: rhesus macaque, not human.
- Duration: 28 days, a single cycle.
- Route: daily subcutaneous injection, dosed by body weight.
- Safety: renal markers moved. The paper identifies the kidney as the dose-limiting organ.
Our adipotide dosage page lays out exactly what each study administered, and our complete guide covers how the molecule was built.
Why there are no human before and after photos
There is a human trial. It is NCT01262664, a first-in-man Phase I run in men with metastatic prostate cancer and obesity. It was not a weight-loss trial in healthy people.
It opened at 0.03 mg/kg. It enrolled four participants. The registry record lists it as terminated with no results posted.
Four people, no posted outcomes. That is the entire human record for adipotide. Any before-and-after image you see attached to this compound was not produced inside a study that reported anything.
Fifteen years after the monkey paper, the obesity program has not advanced. No Phase II. No replication in humans. Nothing in a journal showing a person lost weight on it.
How adipotide works, and why that matters for the photo
Adipotide is a peptidomimetic, also called FTPP. One end finds prohibitin on the blood vessels that feed white fat. The other end triggers apoptosis in those vessels.
It does not change appetite. It does not change how fat is burned. It kills the blood supply to fat tissue, and the tissue dies back.
Targeted ablation of adipose tissue vasculature produced rapid weight loss and reversal of obesity in treated mice.
Kolonin, Saha, Chan, Pasqualini & Arap, Nature Medicine, 2004That 2004 mouse paper is the origin. The 2011 monkey study scaled it up. The mechanism is cytotoxic, not metabolic, and that is the single most important fact about any adipotide photograph.
The kidney was identified as the dose-limiting organ, with renal changes observed at higher exposures in treated monkeys.
Barnhart et al., Science Translational Medicine, 2011Creatinine rose in the animal work above 0.25 mg/kg. A photograph cannot show a kidney. The adipotide benefits page goes through what was and was not demonstrated.
What the photos are competing against
Fat-loss images are the most crowded category in this market. The honest way to read one is against drugs that produced measured results in large human trials.
| Compound | Study | Body-weight change |
|---|---|---|
| Tirzepatide | Phase III SURMOUNT-1 | 22.5% at the top dose |
| Retatrutide | Phase 2 | 24.2% at 48 weeks |
| Adipotide | 2011 rhesus monkeys, 28 days | ~11% mean, range 7.4–14.7% |
| Adipotide | NCT01262664, humans | No results posted |
The incretin rows are Phase III and Phase 2 human data with safety databases behind them. The adipotide rows are a one-month animal study and an empty registry entry. Those are not the same kind of evidence, and a side-by-side photo flattens the difference.
How to read an adipotide before and after
Assume the image is not evidence until it carries the things evidence carries.
- No control. Nobody photographed is being compared to an untreated person doing the same diet.
- No timeline you can check. The monkey result took 28 days under constant supervision. Photo captions rarely say.
- No co-interventions listed. Diet, training, and other compounds are almost never disclosed.
- No labs. The one safety signal in the animal data is renal, and it is invisible in a photograph.
- No verification of what was in the vial. A certificate of analysis tells you more than any image does.
Adipotide is a research compound. It has no approval for any use in people, in any country, and its research-market status is covered on our peptide legality page.
Is there any newer adipotide research?
Not for obesity in humans. The prohibitin-targeting idea has continued in adjacent fields, but not as a successor weight-loss drug.
Hong and Kim published dual-targeting nanoparticle work in Advanced Science in 2022, aimed at fatty liver and adipose tissue together. Hu and colleagues used targeted molecular MRI to measure brown fat activity in 2021. Both are methods papers in the same neighborhood. Neither is adipotide, and neither reports weight loss in people.
So the state of the evidence in 2026 is unchanged from 2011. One monkey study, one terminated four-person trial, and no human before and after anywhere in the literature.
What to know now
- The measured adipotide before and after is 10 rhesus monkeys over 28 days in 2011, averaging about 11% weight loss.
- The human trial NCT01262664 enrolled four people, was terminated, and posted no results.
- The mechanism is cytotoxic: it kills blood vessels feeding white fat. It is not an appetite or metabolic drug.
- The animal data identified the kidney as the dose-limiting organ, with creatinine rising above 0.25 mg/kg.
- For scale, tirzepatide reached 22.5% and retatrutide 24.2% in human trials with full safety databases.
What we're watching
Any adipotide photo presented with a timeline shorter than the 28-day monkey study, or with no mention of renal labs, is marketing and not a result.
Frequently asked questions
Are there real adipotide before and after photos?
Not from any published study. The 2011 Barnhart paper reported weights and imaging in rhesus monkeys, not consumer photos. The only human trial, NCT01262664, enrolled four people and posted no results. Images circulating online are not attached to any reported dataset.
How much weight did adipotide actually cause?
In the 2011 monkey study, ten treated animals lost 7.4% to 14.7% of body weight over 28 days, averaging about 11%. That figure is from rhesus macaques. No equivalent human number has been published.
Why did the human adipotide trial stop?
The registry lists NCT01262664 as terminated with no results posted. It was a Phase I study in men with metastatic prostate cancer and obesity, and it enrolled four participants. The record does not publish an efficacy or safety readout.
Is adipotide safe?
That has not been established in people. The 2011 monkey study identified the kidney as the dose-limiting organ and reported renal changes at higher exposures. With four humans dosed and no published outcomes, there is no human safety dataset to read.
How does adipotide compare to tirzepatide or retatrutide?
It does not compare on evidence. Tirzepatide produced 22.5% mean body-weight reduction in Phase III SURMOUNT-1, and retatrutide produced 24.2% in a Phase 2 trial. Both are human results with large safety databases. Adipotide's best number is from monkeys.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Adipotide deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Uncontrolled, unverified self-report. The pattern in adipotide logs is silence, then null results. The one day-by-day 28-day log in these threads ended with its author reporting she did not drop any pounds. Another user ran it twice and reported zero extra loss, calling any weight change water weight. Dissent exists: one commenter claims about 5 pounds of fat and no side effects. Both threads turn to kidneys within the first few replies.
Where the community and the published record disagree. The rhesus study that made adipotide famous gave 0.43 mg/kg a day, subcutaneously, for four weeks. The Reddit self-experimenters who ran cycles and reported nothing happened were dosing far under that. One logged 4.53 mcg/lb, about 0.01 mg/kg, roughly one fortieth. The other ran 1 mg a day at 215 lb, about the same, then escalated to 3 mg a day at 190 lb, about 0.035 mg/kg or one twelfth, and reported no extra loss at either level. The kidney findings in that same paper, dose-dependent lesions scored minimal to moderate, are what the threads cite when they argue the dose down. So the forums are mostly testing amounts the primate work never tested, then reporting back that the compound does not work. The human record they are arguing over is thinner still: the only trial ever registered, NCT01262664, enrolled 4 men with metastatic prostate cancer and obesity, not dieters, and was terminated at M.D. Anderson.
“I am disappointed to report that the peptide Adipodite (FTPP), did not do anything to help in regards of weight loss.”
“I have done this experiment twice now. I also concluded it sadly this peptide does nothing.”
Comment on "Tracking my usage of Adipotide (FTPP) as a human study"
“went great, no side effects at all except for slightly more bathroom breaks throughout the day. Lost about 5 pounds of straight fat off my frame”
Comment on "Tracking my usage of Adipotide (FTPP) as a human study"
“The lack of answers implies not many attempt it.”
Comment on "Any unofficial reports on n=1 studies on adipotide / fttp?"
“Bostin Loyd joins Dave Palumbo to give an update on his health condition.”
“Adipotide - This Peptide Can KILL You!!”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Barnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H. P., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K.-A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., & Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112. https://doi.org/10.1126/scitranslmed.3002621
- Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 10(6), 625–632. https://doi.org/10.1038/nm1048
- ClinicalTrials.gov. A first-in-man, phase I evaluation of a single cycle of prohibitin targeting peptide 1 in patients with metastatic prostate cancer and obesity (NCT01262664). Terminated; no results posted. https://clinicaltrials.gov/study/NCT01262664
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Hong, J., & Kim, Y. H. (2022). Fatty liver/adipose tissue dual-targeting nanoparticles with heme oxygenase-1 inducer for amelioration of obesity, obesity-induced type 2 diabetes, and steatohepatitis. Advanced Science, 9(33), e2203286. https://doi.org/10.1002/advs.202203286
- Hu, Q., Cao, H., Zhou, L., et al. (2021). Measurement of BAT activity by targeted molecular magnetic resonance imaging. Magnetic Resonance Imaging, 77, 1–6. https://doi.org/10.1016/j.mri.2020.12.006
